Quick Answer
Lineage Cell Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $40.79 million for the year ending 2025.
- Lineage Cell Therapeutics, Inc. showed a decrease of -10.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Lineage Cell Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), Lineage Cell Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 332,101.3%.
- Historical annual values: Fiscal year 2025: $40.79 million | Fiscal year 2024: $45.79 million | Fiscal year 2023: $35.44 million | Fiscal year 2022: $11.36 million | Fiscal year 2021: $55.74 million | Fiscal year 2020: $32.59 million | Fiscal year 2019: $9.50 million | Fiscal year 2018: $23.59 million | Fiscal year 2017: $36.84 million | Fiscal year 2016: $22.09 million | Fiscal year 2015: $42.23 million | Fiscal year 2014: $29.49 million | Fiscal year 2013: $5.50 million | Fiscal year 2012: $4.35 million | Fiscal year 2011: $22.21 million | Fiscal year 2010: $33.32 million | Fiscal year 2009: $12.19 million | Fiscal year 2008: $12.3 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: